Evaluation of crizotinib as radiosensitizer in sacral chordoma cells: effects of combined carbon ion particle therapy
Birgit Lohberger, Dietmar Glänzer, Vanessa Etschmaier, Slave Trajanoski, Andreas Leithner, Beate Rinner, Dietmar Georg · 2025
Read Evaluation of crizotinib as radiosensitizer in sacral chordoma cells: effects of combined carbon ion particle therapy by Birgit Lohberger, Dietmar Glänzer, Vanessa Etschmaier, Slave Trajanoski, Andreas Leithner, Beate Rinner, Dietmar Georg (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12738640.txt.
Description
Birgit Lohberger and six co-authors test a drug as a partner for carbon ion therapy against sacral chordoma, a rare bone tumor near the spine. Their 2025 paper notes that these tumors are hard to remove fully, that chemotherapy helps little, and that carbon ion radiation improves local control. The team asked whether the drug crizotinib, which blocks two growth signals, could make the radiation bite harder.
Two human chordoma cell lines were dosed with carbon ions and studied for growth, cell cycle, and DNA damage responses. The radiation slowed growth somewhat, halted cells at a checkpoint, and switched on repair machinery. The drug cut growth markers and shifted key genes for repair and cell cycle control. It also partly blocked some of the radiation's signaling effects. The authors judge the drug promising on its own for this cancer, but weak as a radiation booster.
Catalog record
| CREATOR | Birgit Lohberger, Dietmar Glänzer, Vanessa Etschmaier, Slave Trajanoski, Andreas Leithner, Beate Rinner, Dietmar Georg |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 39 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |